Does menopausal hormone therapy initiate new breast cancers or promote the growth of existing ones?

Women's Health

Volumn 4, Issue 3, 2008, Pages 207-210

  Santen, Richard J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; PROTEIN BCL 2;

APOPTOSIS; ASPIRATION BIOPSY; AUTOPSY; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EXAMINATION; CANCER GENETICS; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CANCER INVASION; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISEASE COURSE; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EDITORIAL; ESTROGEN DEFICIENCY; FUNCTIONAL PROTEOMICS; GENE MUTATION; HIGH RISK PATIENT; HORMONAL THERAPY; HORMONE ACTION; HUMAN; INTRADUCTAL CARCINOMA; LAVAGE; MAMMOGRAPHY; MENOPAUSE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT CANCER; OVERALL SURVIVAL; POSTMENOPAUSE; REBOUND; RISK ASSESSMENT; RISK REDUCTION;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOGENS; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; TIME FACTORS;

EID: 44649095372     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.4.3.207     Document Type: Editorial

References (33)

1. Greiser CM, Greiser EM, Doren M: Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. Hum. Reprod. Update 11(6), 561-573 (2005).
2. Rossouw JE, Anderson GL, Prentice RL et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3), 321-333 (2002).
3. Welch HG, Black WC: Using autopsy series to estimate the disease 'reservoir' for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann. Intern. Med. 127(11), 1023-1028 (1997).
4. Ryan JA, Coady CJ: Intraductal epithelial proliferation in the human breast - a comparative study. Can. J. Surg. 5, 12-19 (1962).
5. Kriege M, Brekelmans CT, Boetes C et al.: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N. Engl. J. Med. 351(5), 427-437 (2004).
6. Dietel M, Lewis MA, Shapiro S: Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum. Reprod. 20(8), 2052-2060 (2005).
7. Heuser L, Spratt JS, Polk HC Jr: Growth rates of primary breast cancers. Cancer 43(5), 1888-1894 (1979).
8. Sjoblom T, Jones S, Wood LD et al.: The consensus coding sequences of human breast and colorectal cancers. Science 314(5797), 268-274 (2006).
9. Wood LD, Parsons DW, Jones S et al.: The genomic landscapes of human breast and colorectal cancers. Science 318(5853), 1108-1113 (2007).
10. Trichopoulos D, MacMahon B, Cole P: Menopause and breast cancer risk. J. Natl Cancer Inst. 48(3), 605-613 (1972).
11. Feinleib M: Breast cancer and artificial menopause: a cohort study. J. Natl Cancer Inst. 41(2), 315-329 (1968).
12. Vatten LJ, Nilsen TI, Tretli S, Trichopoulos D, Romundstad PR: Size at birth and risk of breast cancer: prospective population-based study. Int. J. Cancer 114(3), 461-464 (2005).
13. Brekelmans CT, Westers P, Faber JA, Peeters PH, Collette HJ: Age specific sensitivity and sojourn time in a breast cancer screening programme (DOM) in The Netherlands: a comparison of different methods. J. Epidemiol. Community Health 50(1), 68-71 (1996).
14. Hofsetb LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ: Hormone replacement therapy with estrogen or estrogen plus medroxyprogescerone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J. Clin. Endocrinol. Metab. 84(12), 4559-4565 (1999).
15. Anderson TJ, Battersby S, King RJ, McPherson K, Going JJ: Oral contraceptive use influences resting breast proliferation. Hum. Pathol. 20(12), 1139-1144 (1989).
16. Santen RJ: Risk of breast cancer with progestins: critical assessment of current data. Steroids 68(10-13), 953-964 (2003).
17. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350(9084), 1047-1059 (1997).
18. Beral V, Million Women SC: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382), 419-427 (2003).
19. Ravdin PM, Cronin KA, Howlader N et al. The decrease in breast-cancer incidence in 2003 in the United States. N. Engl. J. Med. 356(16), 1670-1674 (2007).
20. Robbins AS, Clarke CA: Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J. Clin. Oncol. 25(23), 3437-3439 (2007).
21. Stefanick ML, Anderson GL, Margolis KL et al.: Effects of conjugated equine estrogens on breast cancer and mammograph; screening in postmenopausal women with hysterectomy. JAMA 295(14), 1647-1657 (2006).
22. Chen WY, Manson JE, Hankinson SE et al.: Unpposed estrogen therapy and the risk of invasive breast cancer. Arch. Intern. Med. 166(9), 1027-1032 (2006).
23. Lyytinen H, Pukkala E, Ylikorkala O: Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet. Gynecol. 108(6), 1354-1360 (2006).
24. Espie M, Daures JP, Chevallier T, Mares P, Micheletti MC, De RP: Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. Gynecol. Endocrinol. 23(7), 391-397 (2007).
25. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R: Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283(4), 485-491 (2000).
26. Song RX, Santen RJ: Apoptotic action of estrogen. Apoptosis 8(1), 55-60 (2003).
27. Song RX, Mor G, Naftolin F et al.: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17β-estradiol. J. Natl Cancer Inst. 93(22), 1714-1723 (2001).
28. Jordan VC, Liu H, Dardes R: Re: effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 β-estradiol and the two faces of Janus: sex steroids as mediators of both cell proliferation and cell death. J Natl Cancer Inst. 94(15), 1173-1175 (2002).
29. Lewis JS, Meeke K Osipo C et al.: Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J. Natl Cancer Inst. 97(23), 1746-1759 (2005).
30. Carter AC, Sedransk N, Kelley RM et al.: Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA 237(19), 2079-2078 (1977).
31. Ingle JN: Estrogen as therapy for breast cancer. Breast Cancer Res. 4(4), 133-136 (2002).
32. Dupont WD, Page DL, Parl FF et al.: Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer 85(6), 1277-1283 (1999).
33. Cobleigh MA, Norlock FE, Oleske DM, Starr A. Hormone replacement therapy and high S phase in breast cancer. JAMA 281(16), 1528-1530 (1999).